A method of monitoring disease progression of a patient receiving treatment with a therapeutic agent that binds to and modulates IFN± activity comprising: obtaining a first IFN±-inducible PD marker expression profile in a first sample from the patient； administering a therapeutic agent that binds to and modulates IFN± activity； obtaining a second IFN±-inducible PD marker expression profile in a second sample from the patient； and comparing the first and the second IFN±-inducible PD marker expression profiles, wherein a variance in the first and the second IFN±-inducible PD marker expression profiles indicates a level of efficacy of the therapeutic agent that binds to and modulates IFN± activity.
